In a study by Mutsaers et al., TGFA levels were also increased in a dose-dependent manner in the plasma of EGFR-negative colon cancer patients during cetuximab treatment [25]; however, increased TGFA levels did not associate with cetuximab response in a colon cancer clinical trial [28]. The gene discussed is EGFR; the disease is colonic neoplasm.